Drug Approvals International – Page 93 – All about Drugs Live by Dr Anthony Melvin Crasto

Unoprostone

Unoprostone Molecular FormulaC22H38O5 Average mass382.534 Da [1R-[1a(Z),2b,3a,5a]]-7-[3,5-Dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoic acid 120373-36-6 [RN] 13,14-Dihydro-15-keto-20-ethyl-PGF2a 6920 6X4F561V3W CAS Registry Number: 120373-36-6 CAS Name: (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoic acid Additional Names: 13,14-dihydro-15-keto-20-ethyl-PGF2a Molecular Formula: C22H38O5 Molecular Weight: 382.53 Percent Composition: C 69.08%, H 10.01%, O 20.91% Literature References: Prepn: R. Ueno et al., EP 289349; eidem, US 5221763 (1988, 1993 both to Ueno). Pharmacological characterization: Y. Goh, J. Kishino, Jpn. J. Ophthalmol. 38, 236 (1994). Mechanism of action study: M. Sakurai et …

HEC-68498

HEC-68498, CT-365 CAS 1621718-37-3 C20 H13 F2 N5 O3 S 441.41 Benzenesulfonamide, N-[5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluoro- N-[5-(3-Cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluorobenzenesulfonamide HEC Pharm , Calitor Sciences Llc; Sunshine Lake Pharma Co Ltd PHASE 1, idiopathic pulmonary fibrosis and solid tumors Phosphoinositide 3-kinase inhibitor; mTOR inhibitor Originator HEC Pharm Developer HEC Pharm; Sunshine Lake Pharma Class Anti-inflammatories; Antifibrotics; Isoenzymes Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors Phase I Idiopathic pulmonary fibrosis 22 …

GNE-0877

GNE-0877 Maybe DNL-151 ? CAS 1374828-69-9 Chemical Formula: C14H16F3N7 Molecular Weight: 339.31895 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile Denali Therapeutics Inc, useful for treating Alzheimer’s disease, breast tumor, type I diabetes mellitus and Crohn’s disease GNE-0877 is a highly potent and selective LRRK2 inhibitor. Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience research community because it is …

Nicotinamide riboside chloride

1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]pyridin-1-ium-3-carboxamide CAS 1341-23-7 [RN] 3-(aminocarbonyl)-1-β-D-ribofuranosyl-Pyridinium Nicotinamide riboside chloride CAS 23111-00-4 CHLORIDE CAS : 1341-23-7 (cation) 23111-00-4 (chloride) 445489-49-6 (Triflate) 3-Carbamoyl-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium chloride Nicotinamide ribose chloride UNII-8XM2XT8VWI MW 290.7 g/mol 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride C1=CC(=C[N+](=C1)C2C(C(C(O2)CO)O)O)C(=O)N.[Cl-] Nicotinamide riboside; SRT647; SRT-647; SRT 647; Nicotinamide Riboside Triflate, α/β mixture EH-301, nicotinamide riboside chloride,AND pterostilbene,, BY Elysium Health Inc Nicotinamide riboside, also known as NR and SRT647, is …

New patent, Opicapone, WO 2019123066, Unichem

New patent, Opicapone, WO 2019123066, Unichem WO-2019123066 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019123066&tab=PCTDESCRIPTION Process for the preparation of opicapone and its intermediates, useful for treating parkinson’s disease. Bial-Portela has developed and launched opicapone, for treating Parkinson’s disease. Opicapone is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, use as adjunctive therapy for parkinson’s disease. Opicapone was approved by European Medicine Agency …

Quinupramine, キヌプラミン

Quinupramine キヌプラミン 5-(1-azabicyclo[2.2.2]oct-3-yl)-10,11-dihydro-5H-dibenz[b,f]azepine Formula:C21H24N2 MW:304.44 g/mol CAS:31721-17-2 Quinupramine CAS Registry Number: 31721-17-2 CAS Name: 5-(1-Azabicyclo[2.2.2]oct-3-yl)-10,11-dihydro-5H-dibenz[b,f]azepine Additional Names: 10,11-dihydro-5-(3-quinuclidinyl)-5H-dibenz[b,f]azepine Manufacturers’ Codes: LM-208 Trademarks: Kinupril (Bellon); Kevopril (Rhone-Poulenc) Molecular Formula: C21H24N2 Molecular Weight: 304.43 Percent Composition: C 82.85%, H 7.95%, N 9.20% Literature References: Analog of imipramine, q.v. Prepn: C. Gueremy, P. C. Wirth, DE 2030492 (1971 to Sogeras), C.A. 74,141581e (1971). Animal studies: W. Van Dorsser, A. Dresse, Arch. Int. Pharmacodyn. Ther. 208, 373 …

Quizartinib dihydrochloride, キザルチニブ塩酸塩

Quizartinib dihydrochloride キザルチニブ塩酸塩 Formula C29H32N6O4S. 2HCl CAS 1132827-21-4 Mol weight 633.5891 JAPAN, PMDA APPROVED,. 2019/6/18, Vanflyta Quizartinib (AC220) is a small molecule receptor tyrosine kinase inhibitor, originated Ambit Biosciences, and acquired by Daiichi Sankyo, that is currently under development for the treatment of acute myeloid leukaemia. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene.[1] Flt3 mutations are among …

HS-10340

HS-10340 CAS 2156639-66-4 MF C26 H31 N7 O5 MW 521.57 1,8-Naphthyridine-1(2H)-carboxamide, N-[5-cyano-4-[[(1R)-2-methoxy-1-methylethyl]amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(tetrahydro-2-oxo-1,3-oxazepin-3(2H)-yl)methyl]- (R)-N-(5-cyano-4-((1-methoxypropan-2-yl)amino)pyridin-2-yl)-7-formyl-6-((2-carbonyl)-1,3-oxazepine-3-yl)methyl)-3,4-dihydro-1,8-naphthyridin-1(2H)-carboxamide CAS 2307670-65-9 Jiangsu Hansoh Pharmaceutical Group Co Ltd Being investigated by Jiangsu Hansoh, Shanghai Hansoh Biomedical and Changzhou Hengbang Pharmaceutical ; in June 2018, the product was being developed as a class 1 chemical drug in China. Useful for treating liver cancer, gastric cancer and prostate cancer. Use …

CS-3001

CS-3001 BB 7, VX 033 CAS 2159116-56-8 Propanoic acid, 2-[[5-bromo-4-(3-cyclopropyl-5,5-difluoro-4,5,6,7-tetrahydrobenzo[c]thien-1-yl)-4H-1,2,4-triazol-3-yl]thio]-2-methyl- Molecular Weight, 478.37 C17 H18 Br F2 N3 O2 S2 CStone Pharmaceuticals Co Ltd, JUNE 2018 IND FILED CHINA URAT1 inhibitor – useful for treating hyperuricemia and gout. The compound was originally claimed in WO2017202291 , covering thiophene derivative URAT1 inhibitors, useful for treating hyperuricemia and gouty arthritis, assigned to …

TL-487

TL-487 CAS 1469746-55-1 2-Butenamide, N-[3-cyano-7-ethoxy-4-[(4-phenoxyphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)- Molecular Weight, 507.58, MF C30 H29 N5 O3 Teligene Inc(2E)-N-[3-Cyano-7-ethoxy-4-[(4-phenoxyphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-2-butenamide (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide Maleate in anhydrous or monohydrate CAS, 2326561-36-6, AND 2326561-38-8 form are BTK and HER-2 kinase inhibitor useful for treating cancer Useful for treating breast cancer, ovary cancer and colon cancer. are BTK and HER-2 kinase inhibitor useful for treating cancer. Anticancer protein kinase inhibitor The compound …